Atlas Trials

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

Clinical trial NCT05899673 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05899673
Sponsor
Takeda
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Alpha1-Antitrypsin Deficiency
Start date
2023-08-08
Primary completion
2033-05-02
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.